What clinical and pathological features are you using when selecting patients for adjuvant cemiplimab in high-risk CSCC, given the differences between trial inclusion criteria and NCCN guidelines?

Identifying the select patient population who benefits from adjuvant cemiplimab for cSCC is critical. Current staging systems for cSCC are inadequate to specifically identify the tumors at highest risk for relapse and disease-specific death. The majority of high tumor category and 'high risk' cSCC a...

When considering adjuvant treatment after surgery and adjuvant radiation therapy, we consider cemiplimab for patients who meet the inclusion criteria of the C-POST trial or have a risk profile similar to that of this patient population. Notably, a separate trial of pembrolizumab (KEYNOTE-630) was st...

I used the C-POST trial's definition for high-risk cSCC, as I would like my patients to have outcomes similar to those observed in that pivotal trial. The NCCN guideline is meant to be taken as a suggestion, not a prescription. Unfortunately, many payers are now relying on the NCCN guideline for tre...